CJC-1295(without DAC)+ Ipamorelin (5/5mg) – CP10

CJC-1295 + Ipamorelin (5mg/5mg) — Research Peptide Blend

This combination provides CJC-1295 and Ipamorelin as a co-lyophilised research blend, reflecting the most commonly studied GHRH/GHRP combination in the published growth hormone secretagogue literature. The two compounds act on distinct receptor systems with complementary mechanisms, producing amplified GH responses in animal models and clinical research compared to either compound administered independently.

CJC-1295: GHRH Receptor Agonist

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), modified with a Drug Affinity Complex (DAC) that facilitates albumin binding in plasma. This modification extends the half-life from the ~7 minutes of native GHRH to approximately 6-8 days, enabling sustained GHRH receptor stimulation. A Phase 2 clinical trial published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006) demonstrated dose-dependent increases in serum GH and IGF-1 maintained over 6 days post-single administration in healthy adult volunteers.

Ipamorelin: Selective GHRP

Ipamorelin is a synthetic pentapeptide and selective agonist at the ghrelin receptor (GHSR1a). Unlike earlier GHRPs (GHRP-2, GHRP-6), ipamorelin demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or ACTH at research concentrations — a selectivity profile that has made it the preferred GHRP in contemporary research designs. It acts by stimulating GH pulse frequency from the pituitary, complementing CJC-1295’s action on pulse magnitude.

Product Specifications

• Peptides: CJC-1295 DAC (5mg) + Ipamorelin (5mg)
• Format: Co-lyophilised blend, bulk box of 10 vials
• Purity: ≥98% per component, Janoshik HPLC verified
• Testing: Full Janoshik COA available
• Storage: -20°C. 24-month stability lyophilised.

For laboratory research use only. Not for human therapeutic use.